Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Sponsor
- Sen. Lisa Murkowski (R-AK) (R)
- Introduced
- 2026-04-30
- Latest action
- Placed on Senate Legislative Calendar under General Orders. Calendar No. 461. (2026-07-16)
No recorded vote yet
This bill has not received a recorded floor vote. Most bills never do — they are introduced, referred to committee, and go no further. If it reaches a vote, every member's position will appear here.
AI-generated summary. Written by a language model from the bill's official title and description — not by a person, and not a substitute for the bill text. Vote counts, sponsors and dates above come from the official record, not from this summary. How we build this.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends and renews a federal program designed to speed up the development and approval of treatments for amyotrophic lateral sclerosis (ALS), a progressive neurological disease that affects nerve cells controlling voluntary muscles. The bill reauthorizes existing provisions that help ALS patients gain faster access to experimental therapies while they are still being tested, and it likely includes funding or policy changes to support continued research and treatment development. The legislation directly affects ALS patients seeking access to new drugs, researchers and pharmaceutical companies developing treatments, and the FDA agencies overseeing the approval process.
ALS has no cure and causes rapid physical decline, making access to emerging treatments a high priority for patients and advocacy groups. The original program this bill reauthorizes was enacted to allow terminally ill ALS patients to try experimental drugs before standard FDA approval is complete—a policy sometimes called "right to try." The bill's reauthorization reflects ongoing bipartisan support for expediting treatments for serious diseases, though the specific changes or funding levels included in this version would need to be examined as the bill moves through the legislative process to understand its full impact on drug development timelines and patient access.
Key provisions
- The bill reauthorizes a federal program that speeds up development and approval of treatments for amyotrophic lateral sclerosis (ALS).
- The bill extends provisions allowing ALS patients to access experimental therapies while drugs are still undergoing FDA testing.
- The bill supports faster patient access to emerging treatments for ALS, a progressive neurological disease with no cure.
- The bill affects FDA agencies overseeing the drug approval process for ALS treatments.
- The bill likely includes funding or policy changes to support continued ALS research and treatment development.
More bills with recorded votes
Continue through the public record—each page includes the named roll call.
Spot an error? Tell us — corrections take priority.